What is the difference between Melanoma and Squamous Cell Carcinoma in situ Bowens disease? TIA
Melanoma and squamous cell carcinoma (SCC) in situ (also called Bowen's disease) are both skin cancers, but they start in different cells, behave differently, and are treated differently. Both can be found at an early "in situ" stage, which is why they're sometimes confused.
Cell of origin
- Melanoma begins in melanocytes, the pigment-producing cells at the base of the epidermis. According to the NCCN Guidelines for Patients: Melanoma, these cells make melanin, which gives skin its color and helps protect against UV rays. When melanocytes grow uncontrollably, they form melanoma.
- Squamous cell carcinoma in situ (Bowen's disease) begins in squamous cells, the flat cells that make up the outer layers of the epidermis. "In situ" means the abnormal cells are confined to the top layer of skin and haven't invaded deeper. It is a precancerous-to-early-stage form of squamous cell skin cancer, which falls under "non-melanoma" skin cancer.
Behavior and risk
- Melanoma: Even at stage 0 (in situ), melanoma is taken seriously. The NCCN notes that in situ melanoma is very unlikely to spread and is cured when completely removed. However, once melanoma grows deeper, it has a greater tendency to spread through lymph vessels and blood vessels to lymph nodes and distant organs. This is why pathologists measure features like Breslow thickness (how deep it has grown, in millimeters), ulceration, and mitotic rate (how fast cells are dividing).
- SCC in situ (Bowen's disease): This typically presents as a persistent, scaly, red or pink patch. Left untreated, a portion can progress to invasive squamous cell carcinoma, which can occasionally spread. Overall, SCC in situ is generally considered lower risk than invasive melanoma.
Staging and testing
- Melanoma is staged using Breslow thickness, ulceration, and lymph node status. Deeper tumors may involve a sentinel lymph node biopsy (SLNB), and advanced stages may involve imaging and biomarker testing (such as BRAF).
- SCC in situ does not generally require lymph node testing or imaging, since it hasn't invaded below the top skin layer.
Treatment options
These overlap somewhat, but the approach and the surgical margins differ.
Melanoma in situ: The NCCN identifies wide excision surgery (removing the tumor plus a margin of normal-looking skin) as the standard treatment. In hard-to-treat areas like the face, ears, palms, or soles, Mohs micrographic surgery may be considered. For the lentigo maligna type, topical imiquimod cream or radiation may be options when surgery isn't feasible.
SCC in situ (Bowen's disease): Per the NCCN Squamous Cell Skin Cancer Guidelines, options include surgical approaches and several non-surgical (topical or destructive) treatments, such as topical imiquimod or 5-fluorouracil, photodynamic therapy, cryotherapy, and curettage and electrodesiccation. Radiation is also an option for some patients.
Quick comparison
| Feature | Melanoma (in situ) | SCC in situ (Bowen's) | |---|---|---| | Cell type | Melanocytes (pigment cells) | Squamous cells | | Category | Melanoma | Non-melanoma skin cancer | | Typical appearance | New or changing mole/dark spot (see the ABCDE rule) | Scaly, red/pink, slowly growing patch | | Potential to spread if invasive | Higher | Lower | | Standard treatment | Wide excision (or Mohs in select sites) | Surgery or topical, destructive, or light-based options |
Questions to ask your care team
- Which type of cancer does my pathology report show, and what is the exact stage or depth?
- Were my surgical margins clear (negative)?
- Do I need any additional treatment, or just follow-up?
- How often should I have skin checks, and what changes should I watch for?
- If I have a history of both types, how does that affect my screening schedule?
Your pathology report is the best source for which diagnosis applies. If you'd like, you can share it and I can help explain the terms in plain language.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients: Melanoma — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated November 18, 2026. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Melanoma (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with general for Melanoma patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Melanoma
- What is the difference between somatic and germline mutations in Melanoma
- What is the difference between early stage and metastatic Melanoma
- What is the difference between cure, control, and comfort care for Melanoma
- What does stable disease mean on my Melanoma scan results
- How does CAR-T cell therapy work for Melanoma
- Tell me about b cell function and what goes wrong in lymphoma
- How do I decide between surgery and radiation for Melanoma
- What foods help boost white blood cells during Melanoma treatment